Avalo Therapeutics (AVTX) Income from Non-Controlling Interests (2025 - 2026)
Avalo Therapeutics (AVTX) posted Income from Non-Controlling Interests of -$74000.0 for Q1 2026, down 374.07% on a QoQ basis from $27000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
Avalo Therapeutics' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$74000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6000.0 (changed N/A YoY) and the FY2025 annual result came in at $68000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests was -$74000.0 for Q1 2026 at Avalo Therapeutics, down from $27000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $75000.0 in Q3 2025 and bottomed at -$74000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Avalo Therapeutics | 384.44 Mn | 327.29 Mn | - | -74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | -34,000.00 |